compound introduction
Bcl-xL antagonist 2 is a potent, selective, and orally active antagonist of BCL-X L with an IC 50 and K i of 0.091 μM and 65 nM, respectively. Bcl-xL antagonist 2 promotes the apoptosis of cancer cells. Bcl-xL antagonist 2 has the potential for the research of the chronic lymphocytic leukemia (CLL) and non-Hodgkin’s lymphoma (NHL) In Vivo Assessment of Pharmacokinetics (PK) profile of Bcl-xL antagonist 2 (compound 14) in rat . iv (1 mg/kg) po (5 mg/kg) CL p (mL/min/kg) V ss (L/kg) t 1/2 (h) F % 0.47 0.16 6.0 16 MCE has not independently confirmed the accuracy of these methods. They are for reference only. Form:Solid IC50& Target:0.091 μM (BCL-X L )
